Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation

Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 ((177)Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of (177)Lu-DOTATATE therapy, targeted alpha-partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kröcher, Anke, Folprecht, Gunnar, Winzer, Robert, Sergon, Mildred, Bornhäuser, Martin, Kotzerke, Jörg, Brogsitter, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601768/
https://www.ncbi.nlm.nih.gov/pubmed/37900794
http://dx.doi.org/10.1159/000533198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601768/
https://www.ncbi.nlm.nih.gov/pubmed/37900794
http://dx.doi.org/10.1159/000533198

Ejemplares similares